[go: up one dir, main page]

MX2010009270A - Compuestos y metodos para la prevencion o tratamiento de reestenosis. - Google Patents

Compuestos y metodos para la prevencion o tratamiento de reestenosis.

Info

Publication number
MX2010009270A
MX2010009270A MX2010009270A MX2010009270A MX2010009270A MX 2010009270 A MX2010009270 A MX 2010009270A MX 2010009270 A MX2010009270 A MX 2010009270A MX 2010009270 A MX2010009270 A MX 2010009270A MX 2010009270 A MX2010009270 A MX 2010009270A
Authority
MX
Mexico
Prior art keywords
treatment
restenosis
annexin
variant
functional analogue
Prior art date
Application number
MX2010009270A
Other languages
English (en)
Inventor
Johan Frostegard
Knut Pettersson
Ola Camber
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of MX2010009270A publication Critical patent/MX2010009270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Un método para la profilaxis o tratamiento de la reestenosís que comprende administrar una cantidad terapéuticamente efectiva de Anexina A5 o un análogo o variante funcional de la misma a un paciente que necesita dicho tratamiento; un método para el tratamiento de la estenosis en un paciente que comprende realizar una intervención para el tratamiento de la estenosis junto con administrar una cantidad terapéuticamente efectiva de Anexina A5 o un análogo o variante funcional de la misma; una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de Anexina A5 o un análogo o variante funcional de la misma para la profilaxis o tratamiento de la reestenosis; un stent de elución de fármacos, en donde el fármaco es Anexina A5 o un análogo o variante funcional de la misma, y un método para hacer dicho stent.
MX2010009270A 2008-02-22 2009-02-20 Compuestos y metodos para la prevencion o tratamiento de reestenosis. MX2010009270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3080308P 2008-02-22 2008-02-22
PCT/GB2009/000454 WO2009103977A1 (en) 2008-02-22 2009-02-20 Compounds and methods for the prevention or treatment of restenosis

Publications (1)

Publication Number Publication Date
MX2010009270A true MX2010009270A (es) 2010-09-24

Family

ID=40723470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009270A MX2010009270A (es) 2008-02-22 2009-02-20 Compuestos y metodos para la prevencion o tratamiento de reestenosis.

Country Status (15)

Country Link
US (3) US9295716B2 (es)
EP (2) EP2254589B1 (es)
JP (4) JP2011512393A (es)
KR (1) KR101692392B1 (es)
CN (1) CN101969978A (es)
AU (1) AU2009216543B2 (es)
BR (1) BRPI0908194B8 (es)
CA (1) CA2715859C (es)
DK (2) DK2254589T3 (es)
ES (2) ES2733902T3 (es)
HU (2) HUE035034T2 (es)
MX (1) MX2010009270A (es)
PL (2) PL2254589T3 (es)
TR (1) TR201909412T4 (es)
WO (1) WO2009103977A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740557C (en) 2008-10-17 2020-04-14 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
EP2711705A1 (en) 2008-12-19 2014-03-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
HUE030922T2 (en) 2011-04-05 2017-06-28 Annexin Pharmaceuticals Ab Therapeutic and prophylactic procedures, applications and preparations containing annexin A5
GB201322777D0 (en) * 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN111388152B (zh) * 2018-12-27 2021-12-03 元心科技(深圳)有限公司 药物洗脱器械及其制备方法
CN111494608A (zh) * 2020-05-08 2020-08-07 北京大学第三医院（北京大学第三临床医学院） 预防或治疗子痫前期及相关病症的药物及其应用
CN113317879B (zh) * 2021-05-28 2022-06-07 郑州大学第一附属医院 一种预测肝硬化患者tips术后支架再狭窄的试剂盒
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
KR102823180B1 (ko) * 2022-09-08 2025-06-20 건국대학교 글로컬산학협력단 Annexin A5를 코팅하고 항원을 탑재한 나노입자 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US6602281B1 (en) 1995-06-05 2003-08-05 Avantec Vascular Corporation Radially expansible vessel scaffold having beams and expansion joints
US5922020A (en) 1996-08-02 1999-07-13 Localmed, Inc. Tubular prosthesis having improved expansion and imaging characteristics
AU2001237805A1 (en) * 2000-02-08 2001-08-20 Acspurt B.V. Material and method for immobilization of bioactive species
US6602282B1 (en) 2000-05-04 2003-08-05 Avantec Vascular Corporation Flexible stent structure
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US6962903B2 (en) 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
ATE534658T1 (de) * 2002-06-06 2011-12-15 Tze Chein Wun Neue rekombinante antikoagulationsproteine
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20050037052A1 (en) 2003-08-13 2005-02-17 Medtronic Vascular, Inc. Stent coating with gradient porosity
US20060083772A1 (en) 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
JP2007532617A (ja) * 2004-04-15 2007-11-15 アテラ バイオテクノロジーズ エービー アテローム血栓症およびプラーク破壊を予防するためのアネキシンｖ
AU2008337284B2 (en) * 2007-12-18 2014-09-18 Annexin Pharmaceuticals Ab Compounds and methods for the treatment of vascular disease
JP5534033B2 (ja) * 2010-12-17 2014-06-25 日本電気株式会社 通信システム、ノード、パケット転送方法およびプログラム

Also Published As

Publication number Publication date
EP2254589B1 (en) 2017-04-05
HUE044621T2 (hu) 2019-11-28
HUE035034T2 (en) 2018-05-02
EP3216457A1 (en) 2017-09-13
PL2254589T3 (pl) 2017-11-30
ES2733902T3 (es) 2019-12-03
BRPI0908194A2 (pt) 2016-07-05
JP2011512393A (ja) 2011-04-21
KR101692392B1 (ko) 2017-01-03
DK3216457T3 (da) 2019-07-15
US20180140668A1 (en) 2018-05-24
JP5964369B2 (ja) 2016-08-03
AU2009216543B2 (en) 2014-07-24
US9901614B2 (en) 2018-02-27
WO2009103977A1 (en) 2009-08-27
CA2715859A1 (en) 2009-08-27
JP2019081805A (ja) 2019-05-30
JP2016175946A (ja) 2016-10-06
DK2254589T3 (en) 2017-07-10
US9295716B2 (en) 2016-03-29
AU2009216543A1 (en) 2009-08-27
CN101969978A (zh) 2011-02-09
EP2254589A1 (en) 2010-12-01
EP3216457B1 (en) 2019-04-10
CA2715859C (en) 2021-07-20
JP2015007074A (ja) 2015-01-15
JP6889193B2 (ja) 2021-06-18
BRPI0908194B1 (pt) 2022-01-04
US20160250284A1 (en) 2016-09-01
BRPI0908194B8 (pt) 2023-03-28
US20100331970A1 (en) 2010-12-30
TR201909412T4 (tr) 2019-07-22
KR20100122501A (ko) 2010-11-22
PL3216457T3 (pl) 2019-09-30
ES2630013T3 (es) 2017-08-17

Similar Documents

Publication Publication Date Title
MX2010009270A (es) Compuestos y metodos para la prevencion o tratamiento de reestenosis.
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX2009010407A (es) Derivados fluorados de deferiprona.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
UA117570C2 (uk) Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2015DN00376A (es)
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
BRPI1007945A2 (pt) Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
EA201270617A2 (ru) Способы лечения или предотвращения тромбоза стента
EP2061456A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME
MX2010007242A (es) Composiciones farmaceuticas que comprenden granulos de lipasa microbiana purificada y metodos para prevenir o tratar trastornos digestivos.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
PH12015502679A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
WO2011113000A8 (en) Novel ester containing compositions and methods
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
NZ584766A (en) Method, composition, and article of manufacture for providing alpha-1 antitrypsin

Legal Events

Date Code Title Description
FG Grant or registration